Ortiz de Mendibil I, Vizmanos JL, Novo FJ. Signatures of selection in fusion transcripts resulting from chromosomal translocations in human cancer. PLoS One. 2009;4:e4805.
Google ScholarÂ
Latysheva NS, Babu MM. Discovering and understanding oncogenic gene fusions through data intensive computational approaches. Nucleic Acids Res. 2016;44:4487–503.
Google ScholarÂ
Agarwal S, Tafel AA, Kanaar R. DNA double-strand break repair and chromosome translocations. DNA Repair. 2006;5:1075–81.
Google ScholarÂ
Barr FG. Fusion genes in solid tumors: the possibilities and the pitfalls. Expert Rev Mol Diagn. 2016;16:921–3.
Google ScholarÂ
Gasparini P, Sozzi G, Pierotti MA. The role of chromosomal alterations in human cancer development. J Cell Biochem. 2007;102:320–31.
Google ScholarÂ
Mitelman F, Johansson B, Mertens F. The impact of translocations and gene fusions on cancer causation. Nat Rev Cancer. 2007;7:233–45.
Google ScholarÂ
Edgren H, Murumagi A, Kangaspeska S, Nicorici D, Hongisto V, Kleivi K, et al. Identification of fusion genes in breast cancer by paired-end RNA-sequencing. Genome Biol. 2011;12:R6.
Google ScholarÂ
Kaye FJ. Mutation-associated fusion cancer genes in solid tumors. Mol Cancer Ther. 2009;8:1399–408.
Google ScholarÂ
Tognon C, Knezevich SR, Huntsman D, Roskelley CD, Melnyk N, Mathers JA, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367–76.
Google ScholarÂ
Robinson DR, Kalyana-Sundaram S, Wu YM, Shankar S, Cao X, Ateeq B, et al. Functionally recurrent rearrangements of the MAST kinase and Notch gene families in breast cancer. Nat Med. 2011;17:1646–51.
Google ScholarÂ
Ross JS, Wang K, Chmielecki J, Gay L, Johnson A, Chudnovsky J, et al. The distribution of BRAF gene fusions in solid tumors and response to targeted therapy. Int J Cancer. 2016;138:881–90.
Google ScholarÂ
Ross DS, Liu B, Schram AM, Razavi P, Lagana SM, Zhang Y, et al. Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients. Ann Oncol. 2020;31:991–1000.
Google ScholarÂ
Robinson DR, Wu YM, Vats P, Su F, Lonigro RJ, Cao X, et al. Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet. 2013;45:1446–51.
Google ScholarÂ
Clusan L, Le Goff P, Flouriot G, Pakdel F. A closer look at estrogen receptor mutations in breast cancer and their implications for estrogen and antiestrogen responses. Int J Mol Sci. 2021;22:756.
Saatci O, Huynh-Dam KT, Sahin O. Endocrine resistance in breast cancer: from molecular mechanisms to therapeutic strategies. J Mol Med. 2021;99:1691–710.
Google ScholarÂ
Li S, Shen D, Shao J, Crowder R, Liu W, Prat A, et al. Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep. 2013;4:1116–30.
Google ScholarÂ
Veeraraghavan J, Tan Y, Cao XX, Kim JA, Wang X, Chamness GC, et al. Recurrent ESR1-CCDC170 rearrangements in an aggressive subset of oestrogen receptor-positive breast cancers. Nat Commun. 2014;5:4577.
Google ScholarÂ
Lei JT, Shao J, Zhang J, Iglesia M, Chan DW, Cao J, et al. Functional annotation of ESR1 gene fusions in estrogen receptor-positive breast cancer. Cell Rep. 2018;24:1434–44.e7.
Google ScholarÂ
Gou X, Anurag M, Lei JT, Kim BJ, Singh P, Seker S, et al. Transcriptional reprogramming differentiates active from inactive ESR1 fusions in endocrine therapy-refractory metastatic breast cancer. Cancer Res. 2021;81:6259–72.
Google ScholarÂ
Brett JO, Ritterhouse LL, Newman ET, Irwin KE, Dawson M, Ryan LY, et al. Clinical implications and treatment strategies for ESR1 fusions in hormone receptor-positive metastatic breast cancer: a case series. Oncologist. 2023;28:172–9.
Google ScholarÂ
Loo SK, Yates ME, Yang S, Oesterreich S, Lee AV, Wang XS. Fusion-associated carcinomas of the breast: diagnostic, prognostic, and therapeutic significance. Genes Chromosomes Cancer. 2022;61:261–73.
Google ScholarÂ
Mertens F, Johansson B, Fioretos T, Mitelman F. The emerging complexity of gene fusions in cancer. Nat Rev Cancer. 2015;15:371–81.
Google ScholarÂ
Johansson B, Mertens F, Schyman T, Bjork J, Mandahl N, Mitelman F. Most gene fusions in cancer are stochastic events. Genes Chromosomes Cancer. 2019;58:607–11.
Google ScholarÂ
Davare MA, Tognon CE. Detecting and targetting oncogenic fusion proteins in the genomic era. Biol Cell. 2015;107:111–29.
Google ScholarÂ
Yoshihara K, Wang Q, Torres-Garcia W, Zheng S, Vegesna R, Kim H, et al. The landscape and therapeutic relevance of cancer-associated transcript fusions. Oncogene. 2015;34:4845–54.
Google ScholarÂ
Hartmaier RJ, Trabucco SE, Priedigkeit N, Chung JH, Parachoniak CA, Vanden Borre P, et al. Recurrent hyperactive ESR1 fusion proteins in endocrine therapy-resistant breast cancer. Ann Oncol. 2018;29:872–80.
Google ScholarÂ
Lei JT, Gou X, Seker S, Ellis MJ. ESR1 alterations and metastasis in estrogen receptor positive breast cancer. J Cancer Metastasis Treat. 2019;5:38.
Vitale SR, Ruigrok-Ritstier K, Timmermans AM, Foekens R, Trapman-Jansen A, Beaufort CM, et al. The prognostic and predictive value of ESR1 fusion gene transcripts in primary breast cancer. BMC Cancer. 2022;22:165.
Google ScholarÂ
Yates ME, Li Z, Li Y, Guzolik H, Wang X, Liu T, et al. ESR1 fusion proteins invoke breast cancer subtype-dependent enrichment of ligand independent pro-oncogenic signatures and phenotypes. bioRxiv. 2023. https://www.biorxiv.org/content/10.1101/2023.09.18.558175v1.full.
Li L, Lin L, Veeraraghavan J, Hu Y, Wang X, Lee S, et al. Therapeutic role of recurrent ESR1-CCDC170 gene fusions in breast cancer endocrine resistance. Breast Cancer Res. 2020;22:84.
Google ScholarÂ
Jeong JH, Yun JW, Kim HY, Heo CY, Lee S. Elucidation of novel therapeutic targets for breast cancer with ESR1-CCDC170 fusion. J Clin Med. 2021;10;582.
Nagy Z, Jeselsohn R. ESR1 fusions and therapeutic resistance in metastatic breast cancer. Front Oncol. 2022;12:1037531.
Google ScholarÂ
Veeraraghavan J, Ma J, Hu Y, Wang XS. Recurrent and pathological gene fusions in breast cancer: current advances in genomic discovery and clinical implications. Breast Cancer Res Treat. 2016;158:219–32.
Google ScholarÂ
Stephens, McBride PJ, Lin DJ, Varela ML, Pleasance I, Simpson JT ED, et al. Complex landscapes of somatic rearrangement in human breast cancer genomes. Nature. 2009;462:1005–10.
Google ScholarÂ
Giltnane JM, Hutchinson KE, Stricker TP, Formisano L, Young CD, Estrada MV, et al. Genomic profiling of ER(+) breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance. Sci Transl Med. 2017;9:eaai7993.
Soutoglou E, Misteli T. On the contribution of spatial genome organization to cancerous chromosome translocations. J Natl Cancer Inst Monogr. 2008;39:16–9.
Zhang Y, Rowley JD. Chromatin structural elements and chromosomal translocations in leukemia. DNA Repair. 2006;5:1282–97.
Google ScholarÂ
Soutoglou E, Dorn JF, Sengupta K, Jasin M, Nussenzweig A, Ried T, et al. Positional stability of single double-strand breaks in mammalian cells. Nat Cell Biol. 2007;9:675–82.
Google ScholarÂ
Engreitz JM, Agarwala V, Mirny LA. Three-dimensional genome architecture influences partner selection for chromosomal translocations in human disease. PLoS One. 2012;7:e44196.
Google ScholarÂ
Meaburn KJ, Misteli T, Soutoglou E. Spatial genome organization in the formation of chromosomal translocations. Semin Cancer Biol. 2007;17:80–90.
Google ScholarÂ
Roukos V, Misteli T. The biogenesis of chromosome translocations. Nat Cell Biol. 2014;16:293–300.
Google ScholarÂ
Shugay M, Ortiz de Mendibil I, Vizmanos JL, Novo FJ. Genomic hallmarks of genes involved in chromosomal translocations in hematological cancer. PLoS Comput Biol. 2012;8:e1002797.
Google ScholarÂ
Roukos V, Burman B, Misteli T. The cellular etiology of chromosome translocations. Curr Opin Cell Biol. 2013;25:357–64.
Google ScholarÂ
Hogenbirk MA, Heideman MR, de Rink I, Velds A, Kerkhoven RM, Wessels LF, et al. Defining chromosomal translocation risks in cancer. Proc Natl Acad Sci USA. 2016;113:E3649–56.
Google ScholarÂ
Bunting SF, Nussenzweig A. End-joining, translocations and cancer. Nat Rev Cancer. 2013;13:443–54.
Google ScholarÂ
Rabbitts TH. Commonality but diversity in cancer gene fusions. Cell. 2009;137:391–5.
Google ScholarÂ
Osborne CS. Molecular pathways: transcription factories and chromosomal translocations. Clin Cancer Res. 2014;20:296–300.
Google ScholarÂ
Ahmed J, Torrado C, Chelariu A, Kim SH, Ahnert JR. Fusion challenges in solid tumors: shaping the landscape of cancer care in precision medicine. JCO Precis Oncol. 2024;8:e2400038.
Google ScholarÂ
Schram AM, Chang MT, Jonsson P, Drilon A. Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance. Nat Rev Clin Oncol. 2017;14:735–48.
Google ScholarÂ
Jiang P, Li Y, Poleshko A, Medvedeva V, Baulina N, Zhang Y, et al. The protein encoded by the CCDC170 breast cancer gene functions to organize the golgi-microtubule network. EBioMedicine. 2017;22:28–43.
Google ScholarÂ
Wang XS, Prensner JR, Chen G, Cao Q, Han B, Dhanasekaran SM, et al. An integrative approach to reveal driver gene fusions from paired-end sequencing data in cancer. Nat Biotechnol. 2009;27:1005–11.
Google ScholarÂ
Albertson DG, Collins C, McCormick F, Gray JW. Chromosome aberrations in solid tumors. Nat Genet. 2003;34:369–76.
Google ScholarÂ
Hegyi H, Buday L, Tompa P. Intrinsic structural disorder confers cellular viability on oncogenic fusion proteins. PLoS Comput Biol. 2009;5:e1000552.
Google ScholarÂ
Peng Y, Cao S, Kiselar J, Xiao X, Du Z, Hsieh A, et al. A metastable contact and structural disorder in the estrogen receptor transactivation domain. Structure. 2019;27:229–40.e4.
Google ScholarÂ
Terlecki-Zaniewicz S, Humer T, Eder T, Schmoellerl J, Heyes E, Manhart G, et al. Biomolecular condensation of NUP98 fusion proteins drives leukemogenic gene expression. Nat Struct Mol Biol. 2021;28:190–201.
Google ScholarÂ
Zuo L, Zhang G, Massett M, Cheng J, Guo Z, Wang L, et al. Loci-specific phase separation of FET fusion oncoproteins promotes gene transcription. Nat Commun. 2021;12:1491.
Google ScholarÂ
